Forma farmacéutica: Suspensión inyectable depot agonista de la GnRH, disponible en formulaciones estadounidenses de 1, 3 y 4 meses y japonesas de 1 y 3 meses.
Indicación terapéutica: Indicado para cáncer de próstata, endometriosis, fibromas uterinos, cáncer de mama posmenopáusico y pubertad precoz central.
Condiciones de almacenamiento: Conservar refrigerado entre 2 y 8 °C, protegido de la luz, conforme a los requisitos habituales de manejo de los depot de leuprorelina.

Otra información

Descripción adicional:

Luphere Depot, a leuprorelin-based generic equivalent to Lupron/Leuplin, has been sold in Korea since January 2005 and is being developed for the US and Japanese markets. Acting as a GnRH agonist, it is indicated for prostate cancer, endometriosis, uterine fibroids, postmenopausal breast cancer, and central precocious puberty, with 1-, 3-, and 4-month US formulations and 1- and 3-month Japan formulations already researched. The sustained-release depot uses PLGA polymer encapsulation, matches the reference product's pharmacodynamic profile, and is produced in a cGMP facility; the company is seeking an overseas partner to handle bioequivalence studies, registration, and commercialization outside Korea.